<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81733">
  <stage>Registered</stage>
  <submitdate>21/02/2007</submitdate>
  <approvaldate>26/02/2007</approvaldate>
  <actrnumber>ACTRN12607000146493</actrnumber>
  <trial_identification>
    <studytitle>Post-Operative Concurrent Chemo-Radiotherapy Versus Post-Operative Radiotherapy for Cancer of the Head and Neck</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 05.01 - Post-Operative Concurrent Chemo-Radiotherapy (Carboplatin) Versus Post-Operative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck to improve loco-regional relapse</scientifictitle>
    <utrn />
    <trialacronym>TROG 05.01</trialacronym>
    <secondaryid>ClinicalTrials.gov ID NCT00193895</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Squamous Cell Carcinoma of the Head &amp; Neck (Skin Cancer)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 2: Radiotherapy 60Gy or 66Gy in 30-33 fractions, 5 times a week, over 5-5.5 weeks. Plus, Carboplatin intravenously weekly on either day 1, 2 or 3 of radiation with a max of six doses. Dose of carboplatin is calcualted by a formula that changes the value for each patient. Formula is glomerular filtration rate + 25 x target area under the concentration curve (AUC).</interventions>
    <comparator>Arm 1: Radiotherapy alone 60Gy or 66Gy in 30-33 fractions, 5/week over 5 weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Loco-regional relapse - Time to loco-regional relapse from the date of randomisation.</outcome>
      <timepoint>Follow up visits are scheduled at 4, 8 and 12 weeks, then 6, 9, 12, 16, 20 and 24 months from completion of treatment and then 6 monthly intervals until the final patient has reached a minimum of 2 years follow up.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease free survival</outcome>
      <timepoint>Time from randomisation to the first relapse of any type. Follow up visits are scheduled at 4, 8 and 12 weeks, then 6, 9, 12, 16, 20 and 24 months from completion of treatment and then 6 monthly intervals until the final patient has reached a minimum of 2 years follow up. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival </outcome>
      <timepoint>Time from randomisation till death from any cause. Follow up visits are scheduled at 4, 8 and 12 weeks, then 6, 9, 12, 16, 20 and 24 months from completion of treatment and then 6 monthly intervals until the final patient has reached a minimum of 2 years follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Assessments will be carried out pre-randomisation and the 12 weeks, 6, 12 and 24 months following completion of treatment and annually until the final patient has reached a minimum of 2 years follow up.  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment related late effects</outcome>
      <timepoint>Treatment related acute and late toxicity will be monitored using Common Terminology Criteria Adverse Events v3.0. Follow up visits are scheduled at 4, 8 and 12 weeks, then 6, 9, 12, 16, 20 and 24 months from completion of treatment and then 6 monthly intervals until the final patient has reached a minimum of 2 years follow up.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologically proven Squamous Cell Carcinoma
2. Complete macroscpoic resection of all known disease with or withour microscpoic positive margins. Surgery may consist of one or more of the following:a)Resection of the primary lesion; b) Any type of parotidectomy (superficial, total, partial, etc.); c) Any type of neck dissection(s)
3. High risk feature(s); high risk nodal disease and/or advanced primary disease: a) High Risk Nodal Disease
Intra-parotid nodal disease (any number or size, with/without extracapsular extension, with/without an identifiable index lesion)
b) Cervical nodal disease with a synchronous index lesion or previously resected cutaneous primary tumour (&lt;5 years) within the corresponding nodal drainage and a mucosal primary has been excluded with at least a Computed Tomography (CT) +/- Magnetic Resonance Imaging (MRI) and panendoscopy*
* For cervical nodal disease to be eligible there must be at least one of the following
criteria:
(i) &gt; 2 nodes
(ii) largest node &gt; 3cm
(iii) Extracapsular extension
c) Advanced Primary Disease (Tumor, Node, Metastasis (TNM) 6th Edition 2002) (Appendix 1)
T3-4 primary disease (cartilage, skeletal, muscle, bone involvement, &gt;4cm) of the
head and neck including lip, nose and external auditory canal with or without nodal
disease
d) In transit metastases (metastases between the primary site and the adjoining nodal basin)
4. Age &gt;18 years
5. Written informed consent
6. Eastern Cooperative Oncology Group (ECOG) &lt; 2
7. Absolute neutrophil count &gt; 1.5 X 109/L, platelet count &gt; 100 X 109/L, and haemoglobin &gt; 10g/dL (pre-radiotherapy blood transfusion to elevate the haemoglobin &gt; 10g/dL is permissible)
8. Calculated creatinine clearance (Cockcroft-Gault) &gt;40mL/min
9. Available for follow-up for up to 5 years
10. Life expectancy greater than 6 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Intercurrent illness that will interfere with either the chemotherapy or radiotherapy
such as immunosuppression due to medication or medical condition
2. Metastasis(es) below the clavicle 
3.  Previous radical radiotherapy to the head and neck, excluding treatment of an early glottic cancer &gt; 2 years ago and superficial radiotherapy to cutaneous Squamous Cell Carcinoma (SCC) or basal cell carcinoma
4. High risk for poor compliance with therapy or follow-up as assessed by investigator
5. Pregnant or lactating women
6. Patients with prior cancers, except: those diagnosed &gt; 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or
successfully treated Level 1 cutaneous melanomas or early glottic cancer &gt; 2 years
ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix.
7. Low risk cervical nodal disease* without advanced primary disease
*Low risk cervical nodal disease is defined as the presence of all of the following
criteria;
(i) single nodal metastasis,
(ii) &lt; 3 cm,
(iii) no extracapsular extension.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Stratified allocation. Factors: high risk nodal metastases vs advanced primary disease, institution. Simple randomisation by computer.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/04/2005</anticipatedstartdate>
    <actualstartdate>20/04/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/10/2014</actualenddate>
    <samplesize>350</samplesize>
    <actualsamplesize>321</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/03/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Peter MacCallum Cancer Institute - East Melbourne</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>The Townsville Hospital - Douglas</hospital>
    <hospital>St Andrew's Toowoomba Hospital - Toowoomba</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Illawarra Private Cancer Care &amp; Research Centre - Wollongong</hospital>
    <hospital>Riverina Cancer Care Centre - Wagga Wagga</hospital>
    <hospital>Barwon Health - Geelong Hospital campus - Geelong</hospital>
    <hospital>St Vincents Private Hospital Lismore - Lismore</hospital>
    <hospital>John Flynn - Gold Coast Private Hospital - Tugun</hospital>
    <postcode>4101 - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Trans Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress>Edith ST
Waratah
NSW
2298</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Queensland Cancer Fund</fundingname>
      <fundingaddress>The Cancer Council Queensland, PO Box 201, Spring Hill Qld 4004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Royal Australian and New Zealand College of Radiologists</fundingname>
      <fundingaddress>Level 9
51 Druitt Street
SYDNEY NSW 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Princess Alexandra Hospital</fundingname>
      <fundingaddress>Queensland Health Building
147-163 Charlotte Street
Brisbane Queensland 4000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health research council</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the trial is to determine, in patients who have undergone surgery with curative intent for high-risk CSCC of the head and neck, whether there is a difference in time to loco-regional relapse between patients treated with post-operative concurrent chemo-radiotherapy ,consisting of Carboplatin, and post-operative radiotherapy alone. The target sample size for the trial is 266 patients and will take 3-4 years to accrue, based on an anticipated accrual of 80 patients/year. A further 2 years follow up is required.</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication>Porceddu S, Poulsen M, Bressel M, Stoneley A, Veness M, Kenny L, Wratten C, Corry J, Cooper S, Fogarty G,  Collins M, Collins M, Macann A, Milross C, Penniment M, Panizza B, Rischin D. Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: A randomized phase III trial (Trans Tasman Radiation Oncology Group 05.01 Trial; POST study). J Clin Oncol 35, 2017 (suppl; abstr 6008). 2017 June
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress>Auckland, NZ</ethicaddress>
      <ethicapprovaldate>12/01/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Christchurch, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress>Geelong, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Premion Tugun - John Flynn Cancer Centre</ethicname>
      <ethicaddress>Tugun, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress>Liverpool, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Palmerston North</ethicname>
      <ethicaddress>Papaioea, Manwatu-Wanganui, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Wooloongabba, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>Adelaide, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Herston, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Camperdown, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Townsville Hospital</ethicname>
      <ethicaddress>Townsville, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress>Hamilton, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworthville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress>Darlinghurst, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress>St Leonards, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Andrew's Cancer Care, Toowoomba Hospital</ethicname>
      <ethicaddress>Toowoomba, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Riverina Cancer Care Centre</ethicname>
      <ethicaddress>Wagga Wagga, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>William Buckland Radiotherapy Centre, The Alfred</ethicname>
      <ethicaddress>Prahran, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Sandro Porceddu</name>
      <address>Princess Alexandra Hospital
Oncology Services
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 3176 7853 </phone>
      <fax>+61 7 3176 1983 </fax>
      <email>Sandro.Porceddu@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Sandro Porceddu</name>
      <address>Princess Alexandra Hospital
Oncology Services
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 3176 7853 </phone>
      <fax>+61 7 3176 1983 </fax>
      <email>Sandro.Porceddu@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>TROG Cancer Research
Central Operations Office
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3910  </phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Sandro Porceddu  </name>
      <address>Princess Alexandra Hospital Oncology Services 
Ipswich Road 
Woolloongabba QLD 4102</address>
      <phone>+61 7 3176 7853 </phone>
      <fax>+61 7 3176 1983 </fax>
      <email>Sandro.Porceddu@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>